Umeclidinium Bromide Vilanterol (Anoro Ellipta) (COPD) (Wave 1) | LaunchTrends | US | 2014
This three-wave LaunchTrends report series will track the post-launch awareness, trial, and usage of Anoro Ellipta among pulmonologists for the treatment of chronic obstructive pulmonary disease (COPD) in the United States. The syndicated primary research reports will examine physician perceptions at one month, six months and one year following the commercial availability of Anoro Ellipta. The reports will also investigate where Anoro Ellipta will fit into the treatment algorithm, likely patient candidates, perceived advantages and disadvantages of the product and GlaxoSmithKline’s promotional efforts.
Related Market Assessment Reports
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
Report
Major Depressive Disorder (DSM-V) – Access & Reimbursement – Access & Reimbursement – Major Depressive Disorder (US)
Numerous drugs from multiple drug classes are used as monotherapies and/or adjunctive therapies to treat major depressive disorder (MDD). Early-line treatment is dominated by generically available…
Report
Malignant Melanoma – Unmet Need – Unmet Need – BRAF Wild-Type, Unresectable or Metastatic Malignant Melanoma (US/EU)
Treatment for BRAF wild-type unresectable or metastatic melanoma has been largely shaped by the successive approvals of immune checkpoint inhibitors. Anti-PD-1 agents such as Keytruda (Merck & Co…
Report
Systemic Lupus Erythematosus – Unmet Need – Unmet Need – Moderate to Severe Systemic Lupus Erythematosus (US/EU)
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Report
Systemic Lupus Erythematosus | Unmet Need | Moderate to Severe Systemic Lupus Erythematosus | US/EU | 2024
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
